Biocryst Pharmaceuticals Inc financial data

Symbol
BCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4505 Emperor Boulevard, Suite 200, Durham, NC
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 369 % -33.4%
Quick Ratio 18.9 % -36.6%
Return On Equity 32.1 % -58.5%
Return On Assets -29.5 % +34.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 207M shares +9.18%
Common Stock, Shares, Outstanding 207M shares +9.04%
Entity Public Float 1.32B USD
Common Stock, Value, Issued 2.07M USD +9.02%
Weighted Average Number of Shares Outstanding, Basic 206M shares +9.15%
Weighted Average Number of Shares Outstanding, Diluted 206M shares +9.15%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 201M USD -10.9%
Costs and Expenses 443M USD +5.49%
Operating Income (Loss) -60.3M USD +46.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -146M USD +38.9%
Income Tax Expense (Benefit) -564K USD -119%
Net Income (Loss) Attributable to Parent -146M USD +39.9%
Earnings Per Share, Basic -0.73 USD/shares +43.4%
Earnings Per Share, Diluted -0.73 USD/shares +43.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 78.4M USD -46.4%
Accounts Receivable, after Allowance for Credit Loss, Current 68.8M USD +19.2%
Inventory, Net 4.45M USD -83.5%
Assets, Current 363M USD -28.9%
Property, Plant and Equipment, Net 7.66M USD -9.19%
Operating Lease, Right-of-Use Asset 8.54M USD +22.9%
Other Assets, Noncurrent 12.5M USD +79.3%
Assets 472M USD -10.8%
Accounts Payable, Current 7.79M USD -43.9%
Employee-related Liabilities, Current 36.5M USD +65.1%
Accrued Liabilities, Current 89.6M USD +19%
Liabilities, Current 129M USD +38%
Operating Lease, Liability, Noncurrent 8.36M USD +44.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 557K USD -19.3%
Retained Earnings (Accumulated Deficit) -1.73B USD -9.22%
Stockholders' Equity Attributable to Parent -476M USD -22.4%
Liabilities and Equity 472M USD -10.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -53.7M USD -13%
Net Cash Provided by (Used in) Financing Activities -1.05M USD -121%
Net Cash Provided by (Used in) Investing Activities 28.8M USD
Common Stock, Shares Authorized 450M shares 0%
Common Stock, Shares, Issued 207M shares +9.04%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -26.3M USD +82.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.99M USD -30.2%
Deferred Tax Assets, Valuation Allowance 437M USD +12.2%
Deferred Tax Assets, Gross 441M USD +12.6%
Operating Lease, Liability 9.39M USD +12.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -146M USD +39.7%
Lessee, Operating Lease, Liability, to be Paid 15.5M USD +16.1%
Property, Plant and Equipment, Gross 19.1M USD +5.25%
Operating Lease, Liability, Current 1.03M USD -59.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.66M USD -10.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.85M USD -21.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +9.71%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.15M USD +21.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.58M USD +77.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 14.4M USD +3.74%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.42M USD +128%
Operating Lease, Payments 2.02M USD +44%
Additional Paid in Capital 1.25B USD +4.95%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 306K USD -24.4%
Share-based Payment Arrangement, Expense 13.2M USD +2.59%
Interest Expense 101M USD -5.93%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%